Northrop Grumman (NYSE:NOC – Get Free Report) posted its quarterly earnings data on Thursday. The aerospace company reported $6.39 EPS for the quarter, topping analysts’ consensus estimates of $6.27 by $0.12, Zacks reports. Northrop Grumman had a return on equity of 26.57% and a net margin of 5.79%. Northrop Grumman updated its FY 2025 guidance to 27.850-28.250 EPS.
Northrop Grumman Stock Performance
Northrop Grumman stock traded down $5.02 during trading on Thursday, hitting $476.52. The stock had a trading volume of 639,641 shares, compared to its average volume of 829,497. Northrop Grumman has a 1 year low of $418.60 and a 1 year high of $555.57. The company has a quick ratio of 0.97, a current ratio of 1.09 and a debt-to-equity ratio of 1.00. The stock’s 50 day moving average is $478.66 and its two-hundred day moving average is $497.63. The stock has a market cap of $69.43 billion, a price-to-earnings ratio of 29.38, a price-to-earnings-growth ratio of 0.95 and a beta of 0.35.
Northrop Grumman Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 18th. Stockholders of record on Monday, December 2nd were issued a $2.06 dividend. This represents a $8.24 annualized dividend and a dividend yield of 1.73%. The ex-dividend date was Monday, December 2nd. Northrop Grumman’s dividend payout ratio is presently 51.05%.
Analyst Ratings Changes
Several brokerages have recently issued reports on NOC. Barclays decreased their price target on Northrop Grumman from $550.00 to $500.00 and set an “equal weight” rating on the stock in a research note on Monday, January 6th. Wells Fargo & Company raised Northrop Grumman from an “equal weight” rating to an “overweight” rating and set a $595.00 target price on the stock in a report on Wednesday, January 8th. JPMorgan Chase & Co. lifted their target price on Northrop Grumman from $500.00 to $560.00 and gave the stock a “neutral” rating in a report on Monday, October 14th. UBS Group boosted their price objective on Northrop Grumman from $614.00 to $643.00 and gave the company a “buy” rating in a research note on Friday, October 25th. Finally, TD Cowen raised Northrop Grumman to a “hold” rating in a research report on Tuesday, October 8th. Eight analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $550.94.
Check Out Our Latest Stock Report on NOC
Insider Activity at Northrop Grumman
In other Northrop Grumman news, VP Benjamin R. Davies sold 1,156 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $532.93, for a total transaction of $616,067.08. Following the sale, the vice president now owns 537 shares in the company, valued at $286,183.41. This represents a 68.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders have sold 1,255 shares of company stock worth $663,859. Insiders own 0.22% of the company’s stock.
Northrop Grumman Company Profile
Northrop Grumman Corporation operates as an aerospace and defense technology company in the United States, Asia/Pacific, Europe, and internationally. The company’s Aeronautics Systems segment designs, develops, manufactures, integrates, and sustains aircraft systems. This segment also offers unmanned autonomous aircraft systems, including high-altitude long-endurance strategic ISR systems and vertical take-off and landing tactical ISR systems; and strategic long-range strike aircraft, tactical fighter and air dominance aircraft, and airborne battle management and command and control systems.
Recommended Stories
- Five stocks we like better than Northrop Grumman
- 3 Grocery Stocks That Are Proving They Are Still Essential
- How Value Investors Find Undervalued Stocks and Build Wealth
- What is the Dogs of the Dow Strategy? Overview and Examples
- Is Tonix Pharmaceuticals the Next Biotech Breakout?
- What to Know About Investing in Penny Stocks
- DeepSeek Dip: Is the Nuclear Energy Sell-Off a Buying Opportunity
Receive News & Ratings for Northrop Grumman Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northrop Grumman and related companies with MarketBeat.com's FREE daily email newsletter.